obecabtagene autoleucel (AUTO1) News

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
Enrollment open, CAR T-Cell Therapy:  ALLCAR19: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (clinicaltrials.gov) -  Nov 23, 2020
P1, N=50, Recruiting,  Sponsor: University College, London
Active, not recruiting --> Recruiting

|||||||||| AUTO1 / Autolus, AUTO3 / Autolus
#Autolus #AUTO1 #ALLCAR19 #ASH2020 #AUTO3 #Celltelligence #CART #CellTherapy (Twitter) - Nov 9, 2020

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
New P1 trial, CAR T-Cell Therapy:  CAROUSEL: Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma (clinicaltrials.gov) -  Jun 22, 2020
P1, N=12, Not yet recruiting,  Sponsor: University College, London

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
New P1/2 trial, CAR T-Cell Therapy:  FELIX: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (clinicaltrials.gov) -  May 26, 2020
P1/2, N=145, Recruiting,  Sponsor: Autolus Limited

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy:  ALLCAR19: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (clinicaltrials.gov) -  Mar 31, 2020
P1, N=50, Active, not recruiting,  Sponsor: University College, London
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=20 --> 50 | Trial completion date: Nov 2024 --> Nov 2032 | Trial primary completion date: Apr 2020 --> Sep 2022

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, AUTO3 / Autolus
Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_3793;
Patients receive lymphodepletion with 30 mg/m2/day fludarabine x 4 days and 500 mg/m2/day cyclophosphamide x 2 days prior to AUTO3 infusion...One patient (10%) had prior anti-CD19 CAR-T cells...Only one patient was treated with tocilizumab and none required admission to ICU due to CRS...The most common cause of relapse was antigen positive relapse due to lack of CAR T cell persistence. Evaluation of patients with a modified manufacturing process is planned.

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
Enrollment open, Trial initiation date, CAR T-Cell Therapy:  ALLCAR19: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (clinicaltrials.gov) -  Oct 6, 2017
P1, N=20, Recruiting,  Sponsor: University College, London
Evaluation of patients with a modified manufacturing process is planned. Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Sep 2017

||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
Trial initiation date, CAR T-Cell Therapy:  ALLCAR19: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (clinicaltrials.gov) -  May 11, 2017
P1, N=20, Not yet recruiting,  Sponsor: University College, London
Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Sep 2017 Initiation date: Apr 2017 --> Jul 2017



	Diseases Companies Products Productz Mechanisms of Action Sites